TUMOR NECROSIS FACTOR-ALPHA LEVEL IN SERA OF SOUTH INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATION WITH ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODY LEVEL

Authors

  • Natesan Manikandan PRESIDENCY COLLEGE, CHENNAI
  • Narasingam Arunagirinathan PRESIDENCY COLLEGE, CHENNAI
  • Priya k PRESIDENCY COLLEGE, CHENNAI
  • Nallusamy Vijaykanth PRESIDENCY COLLEGE, CHENNAI
  • Marimuthu Ragavan Rameshkumar PRESIDENCY COLLEGE, CHENNAI
  • Sethuramalingam Balakrishnan PRESIDENCY COLLEGE, CHENNAI

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i1.14274

Abstract

Objective: The present study was aimed to find out the anticyclic citrullinated peptide (CCP) antibody level and expression level Th2 cytokine-liketumor necrosis factor-alpha (TNF-α) in patients with rheumatoid arthritis (RA) from South India.

Methods: The patients attending the Arthritis and Rheumatism Care Centre, Vadapalani, Chennai and healthy individuals from the Presidency College, Chennai, were enrolled for this study. The study group included 74 patients with RA and 50 healthy individuals without history of RA. 3-5 ml of blood samples was aseptically collected using Vacutainer, and the separated serum samples were transported to the Department of Microbiology, Presidency College, Chennai, Tamil Nadu, in cold chain. Anti-CCP antibodies were detected by enzyme-linked immunosorbent assay (ELISA). Serum concentrations of TNF-α were studied in patients with RA and in healthy controls, using an ELISA method.

Results: The results of anti-CCP enzyme immunoassay revealed that out of 74 patients, all were anti-CCP positive, which included 65 females and 9 males. Higher levels of anti-CCP (456 IU/ml) were present in the age group between 41 and 50 followed by 21-30 years age group which shows 335.28 IU/ml of anti-CCP antibody level. The level of serum TNF-α was measured in the range of 4.6-1082.84 pg/ml for RA patients and6.630-459.74 pg/ml for the healthy control group.

Conclusion: TNF-α levels were significantly increased in RA patients compared to healthy individuals. A negative correlation was found between anti- CCP antibody and TNF-α level in RA patients.

Keywords: Rheumatoid arthritis, Tumor necrosis factor-alpha, Enzyme-linked immunosorbent assay, Anticyclic citrullinated peptide antibodies

Downloads

Download data is not yet available.

References

Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev 2010;9(4):216-23.

Alamanos Y, Voulgari V, Drosos A. Rheumatoid arthritis in Southern Europe: Epidemiological, clinical, radiological and genetics considerations. Curr Rheumatol Rev 2005;1:33-6.

van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6(1):37-41.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-81.

Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.

Danis VA, Franic GM, Rathjen DA, Laurent RM, Brooks PM. Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulphasalazine. Ann Rheum Dis

;51(8):946-50.

Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7.

Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: Preclinical and clinical studies. Joint Bone Spine 2002;69(1):12-8.

Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163(3):1521-8.

Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002;69(2):123-32.

Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti- cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008;41(13):1074-7.

Liao J, Ip WS, Cheung KY, Wan WM, Cautherley GW, Cai X, et al. Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis. Clin Chim Acta

;412(9-10):778-81.

Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002;46(3):654-62.

Published

01-01-2017

How to Cite

Manikandan, N., N. Arunagirinathan, P. k, N. Vijaykanth, M. R. Rameshkumar, and S. Balakrishnan. “TUMOR NECROSIS FACTOR-ALPHA LEVEL IN SERA OF SOUTH INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATION WITH ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODY LEVEL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 1, Jan. 2017, pp. 118-20, doi:10.22159/ajpcr.2017.v10i1.14274.

Issue

Section

Original Article(s)